INGENUITY CREATES MILESTONES

OF INTELLIGENT MANUFACTURING

MicroPort®太阳集团tcy8722’s Toumai®Single-port Laparoscopic Surgical Robot Receives NMPA Market Approval in China
2025-02-17 GMT+8 AM 08:01

Shanghai, China, 12 March 2025 —— MicroPort® MedBot™ is proud to announce that its Toumai® SP Laparoscopic Surgical Robot has received market approval from the National Medical Products Administration (NMPA) (registration no. 20253010347) in China. This groundbreaking surgical robot is approved for clinical use across a variety of departments, including urology, general surgery, and gynecology.

 

 

The Toumai® SP boasts an innovative, highly integrated single-port design that enables a 2.5cm incision at the belly button, through which three snake-shaped instruments and a snake-shaped endoscope can be inserted. This compact approach excels in complex environments, such as narrow spaces and intricate anatomical structures.


With its small footprint, high adjustability, and minimal space requirements, the robot is  ideal for operating rooms with limited space, improving adaptability in the surgical environment.

 

Other key features of Toumai® SP include: 

 

Multi-degree-of-freedom Snake-shaped Instruments: Toumai® SP features a 3D high-definition flexible electronic endoscope designed with a multi-degree-of-freedom snake-shaped structure. This design provides a wide field of view and eliminates blind spots. With high-quality imaging, low latency, dual-lens synchronous focusing, and personalized pupil distance calibration, it ensures stable images and smooth operation. The endoscope also offers multiple control modes, an extended lifespan, and helps reduce surgical costs.


Crossed Dual C-arm: Toumai® SP adopts crossed dual C-arm technology, enabling a safer fixed-point design. This allows surgeon to precisely control dual robotic arms through a single minimally invasive incision, supporting full abdominal and pelvic surgeries with enhanced flexibility. By eliminating the need for patient repositioning, it helps reduce the risk of tissue damage.

 

This approval marks the launch of MicroPort® MedBot™’s fifth surgical robot, further expanding its portfolio of innovative robotic solutions across various specialties and surgical approaches.

For more information,
please click here.